The effect of mindfulness meditation on sleep quality and negative emotions in stroke patients with heart disease

Efficacy of mindfulness meditation on sleep quality and negative emotions in stroke patients with concurrent coronary heart disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15770131

Enrollment

Registered

2024-06-24

Start date

2023-05-01

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep quality and negative emotions in stroke patients with concurrent coronary heart disease Mental and Behavioural Disorders

Interventions

Eligible stroke patients with concurrent coronary heart disease at the Second Hospital of Hebei Medical University will be selected. The patients will be randomly divided into an intervention group an

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. First onset of ischemic stroke confirmed via imaging, with a prior clear diagnosis of concurrent coronary heart disease 2. Presence of insomnia that appeared either after the stroke or within one month before the stroke onset, with a Pittsburgh Sleep Quality Index (PSQI) score of = 7 3. Self-Rating Anxiety Scale (SAS) score of = 50 and Self-Rating Depression Scale (SDS) score of = 53 4. Clear consciousness, normal cognitive function, and ability to cooperate with treatment 5. Voluntary signing of informed consent by the patient and their family for participation in this trial

Exclusion criteria

Exclusion criteria: 1. Aphasia, abnormal mental behavior post-AIS, or severe consciousness disorders 2. Existence of unstable angina or myocardial infarction within the past two weeks 3. Significant organ dysfunction 4. Patients with malignant tumors 5. Existence of sleep disorders for more than one month before the stroke onset, or sleep disorders caused by medications or other systemic diseases 6. History of allergy to eszopiclone or similar medications

Design outcomes

Primary

Measure	Time frame
The following primary outcome measures will be assessed before the intervention, and/or after 6 and 12 weeks of the intervention: 1. Sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) 2. Anxiety measured using the Self-Rating Anxiety Scale (SAS) 3. Depression measured using Self-Rating Depression Scale (SDS) 4. Motor function measured using the Fugl-Meyer Assessment (FMA)	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

China

Contacts

Public ContactGuangxiao Ni

kll51x6g4@163.com+86 15230161010

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026